Innovations

 

Venovo Venous Stent System

BD (Becton, Dickinson and Company)

www.bardpv.com/portfolio/venovo

(800) 321-4254


KEY FEATURES

• Balanced radial force, compression resistance, and flexibility

• Proven results in nonthrombotic and postthrombotic lesions

• 3-mm flared ends designed to prevent stent migration

• Broad size range (10–20-mm diameters, 40–160-mm lengths)

• Triaxial delivery system designed for placement accuracy

The Venovo venous stent system has received FDA premarket approval for the treatment of symptomatic iliofemoral venous outflow obstruction. The stent is designed with the balance of radial strength, compression resistance, and flexibility needed for the treatment of symptomatic postthrombotic and nonthrombotic iliofemoral lesions.

One-year results from the prospective, multicenter, single-arm VERNACULAR trial involving 170 patients demonstrated the safety and effectiveness of the Venovo venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction. The clinical findings showed a weighted primary patency rate of 88.3%, with a 96.9% patency rate in nonthrombotic lesions and an 81.3% patency rate in postthrombotic lesions, a statistically significant difference from the performance goal of 74%.

The Venovo venous stent system is available in the United States, Europe, Argentina, Australia, Brazil, Egypt, India, Israel, Mexico, Russia, Saudi Arabia, Singapore, and Taiwan.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.